Today, we announced our First Quarter 2026 Financial Results and provided a company update. Read the press release here: https://lnkd.in/gSE4nxb2
Pliant Therapeutics
Biotechnology Research
South San Francisco, California 13,922 followers
About us
Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of integrin-based therapeutics. At Pliant, we share a commitment and a clear passion to drive innovative science towards addressing areas of unmet medical need. Together we believe we have the power to make a difference in the lives of patients. We believe that by harnessing the therapeutic potential of integrin biology and TGF-β modulation, there is a potential to create drug candidates. Pliant is an equal opportunity employer and does not discriminate against any individual or potential candidate based on race, color, religion, sex, national origin, sexual preference or any other legally protected category. Pliant is located in South San Francisco, California, the birthplace of biotechnology. Learn more about how we are the leader in the discovery and development of integrin-based therapeutic at www.PliantRx.com.
- Website
-
http://www.pliantrx.com
External link for Pliant Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2015
- Specialties
- integrins, muscle biology, oncology, muscular dystrophy, Metabolic dysfunction-associated steatohepatitis, MASH, and drug development
Locations
-
Primary
Get directions
331 Oyster Point Blvd
South San Francisco, California 94080, US
Employees at Pliant Therapeutics
Updates
-
Pliant team members will be participating in a fireside chat with RBC Capital Markets’ Brian Abrahams on Tuesday, May 19, 2026 at 11:30 p.m. ET as part of the 2026 RBC Capital Markets Global Healthcare Conference. Details: https://lnkd.in/g-USKQ-R #RBCHealthcare
-
-
We are excited to announce the dosing of the first patient in our FORTIFY Phase 1b indication expansion trial. This trial is evaluating PLN-101095, our novel dual integrin inhibitor, in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-refractory solid tumors. While ICIs have transformed cancer care, approximately 70–85% of patients with solid tumors do not respond to or develop resistance to them. Read more about FORTIFY, today’s news and how Pliant is focused on addressing underserved areas of medical need: https://lnkd.in/gQKq2VTC
-
-
In an oral presentation today, UT MD Anderson's Dr. Timothy Yap presented updated results from our Phase 1 trial of PLN-101095 in patients with ICI-refractory solid tumors as part of the American Association for Cancer Research's 2026 Annual Meeting. Review the data and presentation https://lnkd.in/gCvrb5fQ #AACR26
-
-
We are pleased to announce that data from our Phase 1 clinical trial of PLN-101095 was selected for an oral presentation as part of the Clinical Trials Mini Symposium session at the 2026 Annual Meeting of the American Association for Cancer Research. Presentation details https://lnkd.in/gmA6eqXh #AACR26
-
-
Today we announced our Fourth Quarter 2025 Financial Results and provided a company update. Review the press release here: https://lnkd.in/g23DEQ-R
-
-
Pliant team members will be participating in a fireside chat on Wednesday, February 25, 2026, at 2:40 p.m. E.T. as part of Oppenheimer & Co. Inc.’s 36th Annual Healthcare Life Sciences Conference. #OPCOLifeSciences Details: https://lnkd.in/gW27Cx7Z
-
-
Join a team of committed, collaborative and compassionate individuals focused on improving the lives of patients. We’re looking for a strategic, forward-thinking regulatory leader with extensive oncology expertise to help shape the future of our oncology program and influence the direction of Pliant’s growing early-stage portfolio. Learn more about this opportunity and apply here: https://lnkd.in/gzt3D-FD #RegulatoryAffairs, #RegulatoryStrategy, #RegulatoryOperations, #Oncology, #Hiring
-
-
Today we announced encouraging interim data from our Phase 1 trial of PLN-101095 in patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors. We welcome you to review the press release https://lnkd.in/gZqX99PC and listen to our senior leadership discuss these data today at 12:30 pm ET as part of a Piper Sandler fireside chat: https://lnkd.in/gep-MAFx.
-
-
Pliant team members will be participating in a fireside chat on Thursday, December 4, 2025 at 12:30 p.m. ET as part of Piper Sandler’s 37th Annual Healthcare Conference. Details: https://lnkd.in/gKd4JrSi
-